Alembic Pharmaceuticals posts strong Q4 FY26 growth as net profit jumps 29%

US formulations grew 11% to Rs. 564 crore as Alembic enters US branded pharmaceuticals market with launch of Pivya

Akums Q4 revenue climbs to Rs. 1,158 crore; PAT surges 135%

FY26 revenue rises to Rs. 4,359 crore as India’s leading CDMO strengthens global footprint with EU GMP certifications, UK MHRA approval and Europe supplies

Gland Pharma posts record revenue, nearly doubles profit in Q4 FY26

The 38% adjusted EBITDA margin of base business has been supported by robust growth in the CDMO segment

OneSource records Rs. 4,282 million revenue in Q4 FY26

Backed by Semaglutide launches, the company reported 47% quarter-on-quarter revenue growth in Q4 FY26, with EBITDA expanding more than fivefold

Akums posts strong FY26 performance as EBITDA surges 61.6% in Q4

JB Chemicals reports muted Q4 FY26 as integration resets business

The CDMO segment saw a 22% decline in Q4 due to a strong base in the prior year

Artemis Medicare Q4 FY26 revenue rises 16.4% to Rs. 27,923 lakh, net profit jumps 32.1%

The hospital chain reported strong growth driven by its Gurugram facility, international patient inflow, and operational efficiencies

Lupin Q4 FY26 PBT jumps 115% to Rs 19,280 million

U.S. business drives strong growth as Lupin reports 57% rise in Q4 U.S. sales and 43% increase in gross profit

Thyrocare Q4 PAT surges 128% to Rs. 48.7 crore

Diagnostic major processes 59 million tests in Q4FY26 as revenue rises 20% and specialty testing portfolio expands

Biocon Q4 profit jumps 64%; FY26 revenue crosses Rs. 16,900 crore

The biosimilars business generated Rs. 10,431 crore in FY26 revenue, up 16% year-on-year